Q-Line Biotech IPO Listing Today 29 May 2026: Opens at Rs 445 on NSE SME – 29.7% Gain Over Issue Price Rs 343, GMP Nailed Exactly

May 29, 2026
Posted by: Kunal Singla
Category: IPO

Q-Line Biotech IPO listing today (29 May 2026): opened at Rs 445 on NSE SME – exactly matching the GMP-implied price. +29.7% gain (Rs 102) over issue price Rs 343. Subscribed 987%. India’s largest SME IPO of 2026 delivers for allottees.

The Q-Line Biotech IPO listing today (29 May 2026) delivered exactly what the grey market predicted. The stock opened at Rs 445 on NSE SME – a gain of Rs 102 or 29.7 percent over the issue price of Rs 343. The pre-listing GMP of Rs 102 implied an expected listing at Rs 445, and the Q-Line Biotech IPO listing hit that level precisely on opening. India’s largest SME IPO of 2026 by issue size at Rs 214.48 crore has rewarded its 987 percent subscribed investor base. Allottees who received shares at Rs 343 have a Rs 102 per share gain from Day 1.

Table of Contents

Q-Line Biotech IPO Listing: Key Numbers

Listing Price: Rs 445 on NSE SME (29 May 2026)
Issue Price: Rs 343 per share (upper band)
Listing Gain: Rs 102 per share (+29.7% over issue price)
GMP vs Actual: GMP was Rs 102 – actual listing Rs 445 – perfect match
Subscription: 987% overall | QIB 519% | NII 1,095% | Retail 1,007%
Issue Size: Rs 214.48 crore (India’s largest SME IPO of 2026)
Minimum allotment value at listing: 800 shares × Rs 445 = Rs 3,56,000 (applied at Rs 2,74,400 – gain Rs 81,600 per lot)
Pre-IPO anchor: Vikas Vijaykumar Khemani – Rs 14.94 crore at Rs 343 – thesis validated on Day 1

About Q-Line Biotech: IVD Diagnostics from Lucknow

Q-Line Biotech Limited, founded in 2013 in Lucknow, Uttar Pradesh, manufactures and supplies In-Vitro Diagnostics (IVD) products – reagents, rapid test kits, haematology instruments, diagnostic equipment and pathology instruments. The company serves 150-plus national and international clients. FY25 revenue was Rs 322.58 crore (+56.2% from Rs 206.45 crore in FY24). The Q-Line Biotech IPO listing gain validates investor confidence in the IVD sector thesis – India’s organised diagnostics market is growing at 12-15 percent annually as hospital and lab infrastructure expands.

FY25 Revenue: Rs 322.58 crore (+56.2% YoY)
FY25 PAT: Rs 28.13 crore (vs Rs 34.44 crore in FY24 – PAT declined due to expansion investments)
Products: IVD reagents, rapid test kits, haematology instruments, point-of-care devices
IPO use: Rs 93.50 crore working capital + Rs 90 crore debt repayment + general corporate

Tap to Access Best Research Pieces on Univest

Should Allottees Hold or Book Profit at Rs 445?

The Q-Line Biotech IPO listing at Rs 445 – exactly at the GMP-implied price – creates the classic post-listing decision. At Rs 445, the implied market cap is approximately Rs 1,039 crore. FY25 revenue of Rs 322.58 crore at Rs 1,039 crore market cap implies a Price-to-Sales of approximately 3.2 times – reasonable for a diagnostics manufacturer with 56 percent revenue growth. The PAT decline in FY25 (from Rs 34.44 crore to Rs 28.13 crore) due to expansion investments is a watch item – FY26 PAT recovery will be the key trigger for secondary market performance.

For allottees who applied purely for listing gain: a 29.7 percent gain at opening is a strong outcome for a 5-day blocked capital period. Booking partial profits at Rs 445 and holding the balance for a medium-term target above Rs 500 is a balanced approach. NSE SME stocks can be illiquid in secondary markets – the market maker’s two-sided quote typically supports pricing only up to a limited daily volume. Consult a SEBI-registered advisor before any post-listing trading decision.

Disclaimer: This article is for informational and educational purposes only. Nothing in this article constitutes investment advice, a recommendation to buy or sell securities, or a solicitation of any offer to buy or sell securities. Univest is a SEBI-registered research analyst (INH000014019). Readers should conduct their own research and consult a SEBI-registered investment advisor before making any investment decisions. Past performance of any stock or sector is not indicative of future results. Investments in equity markets are subject to market risks

FAQs on Q-Line Biotech IPO Listing

What is Q-Line Biotech IPO listing price today?

Ans. Q-Line Biotech IPO listing price today (29 May 2026) is Rs 445 on NSE SME – a gain of Rs 102 or 29.7% over the issue price of Rs 343. The pre-listing GMP of Rs 102 was exactly matched at listing. The IPO was subscribed 987% with Vikas Khemani as pre-IPO anchor at Rs 343.

What is Q-Line Biotech’s gain for allottees?

Ans. Allottees who received Q-Line Biotech shares at Rs 343 have a gain of Rs 102 per share (29.7%) at the listing price of Rs 445. For the minimum lot of 800 shares (applied at Rs 2,74,400), the value at listing is Rs 3,56,000 – a gain of Rs 81,600 per lot on Day 1.

IPO Listing Today

Author: Kunal Singla

Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.